The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Broadening access for children & patients with inhibitor-complicated hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Several technologies for hemoglobinopathies are being transferred to commercial partners
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Demonstrate significant bleed reduction in hemophilia A and B
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
